Novartis has entered into a development and licensing agreement with Biological E Limited (BioE), a biopharmaceutical company based in India, for two vaccines to protect against typhoid and paratyphoid fevers. The agreement advances the Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions.
Under the license, NVGH will transfer technology to BioE, which will have financial and operational responsibility for manufacturing, further clinical development, approval and distribution in the developing world. The typhoid vaccine (Vi-CRM197) has achieved Proof of Concept, had successful Phase 2 results, and will be transferred to BioE. A combined typhoid-paratyphoid vaccine will be transferred once Proof of Concept is completed through early, small-scale studies in humans to determine safety and immunogenicity.
In addition, a dual-acting vaccine with components against both typhoid and paratyphoid fevers is being developed with on-going support from the Wellcome Trust. Both could reduce the burden of these diseases in endemic regions.
The typhoid vaccine (Vi-CRM197) has achieved successful clinical proof-of-concept and Phase 2 clinical trials and is now in the process of being transferred to BioE. A combined typhoid-paratyphoid vaccine that is still undergoing testing at NVGH will be transferred to BioE once clinical proof-of-concept will be completed through early, small-scale human studies to determine safety and immunogenicity.
|Location||South Asia, India|